Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae

BACTERIUM: Study for a Machine-learning-based Model to Predict Bloodstream Infections

NCT05876598 ·Status: RECRUITING

Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?

NCT02292160 ·Status: COMPLETED

Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria

NCT06910878 ·Status: RECRUITING

Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France

NCT02799225 ·Status: COMPLETED

Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia

NCT05394298 ·Status: UNKNOWN ·Phase: PHASE4

A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia

NCT01511224 ·Status: UNKNOWN

Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria

NCT03338738 ·Status: COMPLETED ·Phase: NA

Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases

NCT02127450 ·Status: COMPLETED

Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region

NCT02803710 ·Status: UNKNOWN

Antimicrobial Susceptibility for Helicobacter Pylori Eradication

NCT01486082 ·Status: UNKNOWN

Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.

NCT02631226 ·Status: UNKNOWN

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

NCT01820793 ·Status: TERMINATED ·Phase: NA

Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria

NCT01771432 ·Status: UNKNOWN ·Phase: NA

Optimization Management Study of Community Urinary Tract Infections Spectrum

NCT03655548 ·Status: COMPLETED

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

NCT04170309 ·Status: COMPLETED

Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread

NCT02666274 ·Status: UNKNOWN

Empirical Antibiotic and Outcome in Community-onset Bacteremia

NCT03765749 ·Status: COMPLETED

Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients

NCT01838213 ·Status: COMPLETED

ADAPT-AST (Adaptive Antimicrobial Susceptibility Testing)

NCT06297837 ·Status: ACTIVE_NOT_RECRUITING

Optimal Doses for Drug Provocation Tests to Beta-lactams

NCT02839551 ·Status: COMPLETED ·Phase: NA

Pharmacokinetics of Ertapenem in Patients Aged Over 75

NCT02505386 ·Status: COMPLETED ·Phase: PHASE4

Multi-Antibiotic Resistance Carriage in Gut Flora

NCT01591538 ·Status: COMPLETED

Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.

NCT02031588 ·Status: TERMINATED

Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)

NCT03535324 ·Status: COMPLETED ·Phase: NA

Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

NCT06833593 ·Status: RECRUITING